pcar-019
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2016 (NCT02851589)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pcar-019
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02819583 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2016 | Anhui Medical University, Hefei University, PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
| NCT02851589 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2016 | Anhui Medical University, PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anhui Medical University | Academic/Hospital | 2 | 0 | 1 | 2016 |
| PersonGen BioTherapeutics (Suzhou) Co., Ltd. | For profit | 2 | 2 | 1 | 2016 |
| Hefei University | Academic/Hospital | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1